At ImevaX, we develop new vaccines against chronic and nosocomial infections. Our lead product is IMX101, a novel approach to fighting Helicobacter pylori. With this vaccine we will be first in class in the market.
Over half of the world’s population is infected with the bacterium Helicobacter pylori. It can lead to stomach ulcers and is the primary cause of stomach cancer.
Recently, the clinical development plan for our lead product was approved. Now ImevaX is a clinical stage company evaluating IMX101 in a phase I trial.